Back to top
more

Glaukos (GKOS)

(Real Time Quote from BATS)

$89.63 USD

89.63
413,767

+1.57 (1.78%)

Updated Aug 6, 2025 12:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Align Technology (ALGN) Q2 Earnings Lag Estimates, Margins Drop

by Zacks Equity Research

The dull underlying market situation, impacted by macro-economic environmental factors and lingering effects of COVID-19 variants in certain markets, impacts Align Technology's (ALGN) Q2 results.

Zacks Equity Research

Boston Scientific (BSX) Q2 Earnings Beat, Margins Decline

by Zacks Equity Research

Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.

Zacks Equity Research

Henry Schein (HSIC) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) Q2 performance will likely reflect continued strength in its dental and medical businesses.

Zacks Equity Research

IDEXX (IDXX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

IDEXX's (IDXX) Q2 performance will likely benefit from strong sales from the CAG Diagnostics and Water businesses.

Zacks Equity Research

Edwards Lifesciences (EW) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Edwards Lifesciences' (EW) Q2 performance will likely reflect the continued adoption of the RESILIA tissue valves and enhanced sales of the HemoSphere platform.

Zacks Equity Research

Exact Sciences (EXAS) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Exact Sciences' (EXAS) Q2 performance will likely reflect the benefit from continued adoption of the Oncotype DX breast test and robust Cologuard screening revenues.

Zacks Equity Research

Charles River (CRL) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.

Zacks Equity Research

STERIS (STE) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

STERIS' (STE) Key Surgical and Cantel Medical businesses make significant contributions to consumable revenues within the Healthcare arm in Q1.

Zacks Equity Research

DaVita (DVA) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Supply constraints, along with inflationary pressures, is likely to have weighed on DaVita's (DVA) second quarter's top line.

Zacks Equity Research

Intuitive Surgical (ISRG) Q2 Earnings Miss, Procedures Recover

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results reflect health demand for procedures despite the resurgence of COVID-19 infections.

Zacks Equity Research

Here's Why Glaukos (GKOS) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Glaukos (GKOS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Is a Beat Likely for Intuitive Surgical (ISRG) in Q2 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.

Zacks Equity Research

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Zacks Equity Research

Best Momentum Stocks to Buy for July 13th

by Zacks Equity Research

JAZZ, GKOS and SPPI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13, 2022.

Zacks Equity Research

Here's Why You Should Add Glaukos (GKOS) to Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

Has Glaukos (GKOS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Glaukos (GKOS) and Alkermes (ALKS) have performed compared to their sector so far this year.

Zacks Equity Research

New Strong Buy Stocks for July 13th

by Zacks Equity Research

KMI, UFCS, GKOS, SPPI and BECN have been added to the Zacks Rank #1 (Strong Buy) List on July 13, 2022.

Zacks Equity Research

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Zacks Equity Research

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Zacks Equity Research

Glaukos (GKOS) Stock Falls 25.9% Despite Q1 Earnings Beat

by Zacks Equity Research

Glaukos' (GKOS) soft Q1 results fail to impress investors.

Zacks Equity Research

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 26.92% and 11.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Despite reporting a fourth-quarter loss, Glaukos' (GKOS) results reflect a noticeable rise in revenues.

Zacks Equity Research

Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 16.22% and 8.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?